Factor VIII half-life and clinical phenotype of severe hemophilia A

Van Creveldkliniek, UMCU, Room C01.425 PO-Box 85500, 3508 GA Utrecht, The Netherlands. k.vandijk@azu.nl

BACKGROUND AND OBJECTIVES: Patients with severe hemophilia A have considerably different factor VIII half-lives. Whether this is associated with their clinical characteristics has not been reported. The aim of this study was to describe the association of factor VIII half-lives with treatment and clinical characteristics of patients with severe hemophilia A, who have been treated with individually tailored prophylaxis. DESIGN AND METHODS: Patients were selected from a single-center cohort of 214 patients with severe hemophilia, born between 1944 and 1995. To improve efficiency we measured factor VIII half-life in 42 patients selected from the extremes of the distribution of phenotypes of severe hemophilia. We assessed information on life-long joint bleeds and clotting factor consumption. Orthopedic outcome was assessed by the Pettersson score. RESULTS: Among these patients with severe hemophilia, factor VIII half-life ranged from 7.4-20.4 hours (median 11.8 hours). A one-hour increase in factor VIII half-life was associated with 96 (95% confidence interval (CI) 2 -190) IU less clotting factor use per kg per year. Age was an important determinant of factor VIII half-life, and explained a large part of the association between factor VIII half-life and clotting factor consumption. The median number of joint bleeds per year and arthropathy were similar for patients with different half-lives. INTERPRETATION AND CONCLUSIONS: Among patients with severe hemophilia, treated prophylactically with clotting factor, those with a shorter factor VIII half-life required slightly more clotting factor to prevent joint bleeds and subsequent arthropathy than similar patients with a longer factor VIII half-life.

This article has been cited by other articles:

				S. Planque, M. A. Escobar, K. C. Smith, H. Taguchi, Y. Nishiyama, E. Donnachie, K. P. Pratt, and S. Paul Covalent Inactivation of Factor VIII Antibodies from Hemophilia A Patients by an Electrophilic FVIII Analog J. Biol. Chem., May 2, 2008; 283(18): 11876 - 11886. [Abstract] [Full Text] [PDF]

				G. Roosendaal and F. Lafeber Prophylactic Treatment for Prevention of Joint Disease in Hemophilia -- Cost versus Benefit N. Engl. J. Med., August 9, 2007; 357(6): 603 - 605. [Full Text] [PDF]